Connect to Frankfurt

In Dec 2021, Thermo Fisher completed the acquisition of PPD, Inc, a leading global provider of clinical research services to the biopharma and biotech industry. With the addition of PPD, Thermo Fisher will offer a comprehensive suite of world-class services across the clinical development spectrum – from s...

Despite being widely commercialised as injectable formats, “biologics” are now creating lots of excitement in the orally inhaled and nasal drug product (OINDP) segment of the pharma industry. But compared to small molecules, one biologic can be fundamentally widely different from next in their properties a...

The pharma industry is aware that it needs to improve the representation of women and minority communities in its businesses. The benefits of diverse teams are clear, yet it isn’t an easy road. How can companies create an environment where people feel safe, thrive, and attract the best?
Approaching ...

The complexity and risks found within the global pharma supply chain cannot be understated and key stakeholders from customers to regulators and investors are increasingly expecting the industry to both manage ESG risks and embed sustainability throughout the value chain. This can only be achieved through ...

• What is the best strategy to access novel therapeutic approaches and technologies? • Licensing vs M&A? • How to build a stake in competitive future therapies and innovations • How to beat competitors to your desired goals • Exploiting innovation arising in non-medical fields and other indust...

The human microbiome enlists all the microorganisms and their related metabolites/products identified in and on the human body. Technological advancement has enabled the assessment of the pleiotropic effects of the human gut microbiome in health and diseases. With the extensive role of microbes in human he...

An investigational large volume subcutaneous wearable injector delivered 5mL viscous placebo injections to healthy adults with favorable subject tolerability and acceptability. This session outlines:
• An investigational large volume subcutaneous wearable injector was evaluated for feasibility of 5...

Worldwide, people are increasingly health-conscious and aware of the impact of individual lifestyle choices on their health and the health of others. In the latest years, consumers seek more and more transparency from companies through their brand, product manufacturing, and actions that promote well-being...

BioPhorum has brought together biomanufacturers, supply partners, engineering partners, and regional innovation hubs to build a consensus strategy roadmap, encompassing considerations for all aspects of development from raw material to product, for the future of the industry. The roadmap will be presented ...

Indena’s view and technology expansion to support partners’ developments.

Supported by more than 100 year experience, Indena has been involved ever since in the CDMO activities on behalf of its partners, even before CDMO was so named. Starting from the extraction, chromatographic purification an...

Asymmetrex® markets the first and only technology for routine counting of therapeutic stem cells, like those in life-saving bone marrow transplants. The patented technology, “kinetic stem cell (KSC) counting,” tells physicians the dosage of stem cells in such treatments. KSC counting also improves bioman...

The acceleration of digital transformation across industries has been a prominent theme in the wake of COVID-19. In the pharmaceutical industry, the pandemic highlighted the need for agility and resiliency within the supply chain, fueling an increased urgency for the adoption of Pharma 4.0 technologies tha...

4040/40 elastomer formulation was designed with ‘future in mind’ to meet the ever-increasing performance & quality standards expected of primary drug packaging. The presentation will summarize the extensive Quality by Design (QbD) process that was undertaken to develop this new formulation as well as consi...

More than 75 % of new chemical entities are poorly soluble and require bioavailability-enhancing excipients. The application of excipients in advanced pharmaceutical processes, such as hot melt extrusion and 3D-printing, aligned with advanced approaches towards personalized medicine, requires special featu...

Indena is relentlessly working to generate a sustainable impact on its stakeholders, cultivating with care its own precious circle: Nature, Technology, and People. In terms of actual projects and actions, Indena's commitment in sustainability includes responsible supply chain management, a circular economy...

This short session answers the most pressuring strategic questions with regards to sustainability: Why does it matter? Where to focus? How is it measured? What is the current industry status? How to improve?

Did you enjoy this session? If so, you might like to visit our Connect to Frankfurt plat...

Future Predictions on Drugs from Sales & Forecast • Looking ahead to see the shape and direction of the Pharma market. • Using Sales and Forecasts to see which areas are predicted to lead or lag. • Identifying key therapy areas and indications as well as molecule types that may come to dominate t...

With this session you will learn about best practices in Green Chemistry metrics for evaluating the impact of waste in pharmaceutical drug substance manufacturing, and their limitations, in the context of API lifecycle assessment. You will also be informed about the new iGAL 2.0 metric as a valuable extens...

Global drug sales have now hit $1 Trillion for the first time; the R&D pipeline has doubled in the last 10 years, CDMO market is expanding at a consistent 10% YOY. The pharma industry faces countless opportunities; however, there is a problem. Business leaders are asking where has all the talent gone? qq...

In this webinar, formulation scientists and pharmaceutical development specialists will learn how Lonza’s Capsule Applications Services lab can address drug solubility limitations, develop innovative capsules to tailor drug delivery, and optimize encapsulation processes.


Click here to ...

Brenntag developed a long-term strategy and strives for the vision to become a “Future Sustainable Brenntag”. Watch our session and get inspired by Dr. Andreas Kicherer and Wolfgang Edel.
This session highlights: • Innovation meets Sustainability → meet our NEW green products and solutions. • C...

The MDR (Medical Device Regulation) requires a detailed evaluation of the clinical data for a Medical Device. It is important that the manufacturers are using the right method and strategy for collecting those PMCF data. PMCF should be linked and part of the PMS and Clinical process. Using the “right” soft...

For the past few years, the traditional one-size-fits-all go-to-market strategy, predominantly based on customer interactions through physical channels, has failed to support drug launches and meet business objectives. Inadequate or incomplete understanding of customer needs has been identified as one of t...

In this presentation, three of Pfizer CentreOne’s technology transfer MVPs present the playbook for a project accelerated by the pandemic.

The team will discuss the vital moments in the project that enabled success at a pace never seen before, including: • The value and need for having all par...

When working with the right partner and network, transferring production between sites allows companies to reap a variety of strategic advantages. Timeline and cost efficiencies can be gained when a trusted CDMO can take a product from development to commercial launch.

They can safeguard supply ...

Pharmaceutical and Biotechnology companies are exposed to more than their fair share of ESG risks, that, if not addressed properly, can have significant financial and reputational impacts in the long run. To measure a company’s level of exposure with industry-specific material ESG risks and how well a comp...

For the past few years, the traditional one-size-fits-all go-to-market strategy, predominantly based on physical channels, has failed to support drug launches and meet business objectives. Inadequate or incomplete understanding of customer needs has been identified as one of the top-3 root causes.
T...

Improving the sustainability in the CDMO industry is a multi-facetted approach covering environmental, economic and social tasks while having a strong focus on these areas where a company can make the highest impact. Bachem, the leading manufacturer of peptides and oligonucleotides is a good example for us...

CPHI is back in Frankfurt, an important hub for the German pharmaceutical community. This session will explore the German market and look at the abundance of innovation emerging from one of Europe's biggest pharma hubs.
This session will touch upon: • Access to Innovative Medicines and Launch Pe...

Bringing It Home: The New Generation of Clinical Trials


Click here to register

• Digitalization in biopharma is more complex than just replacing paper documents with electronic counterparts or hiring data scientist • In the context of bioprocessing, the industry needs a better way to transition quickly from lab to clinical to commercial manufacturing • Speed to clinic require...

Nutraceuticals and over-the-counter (OTC) products are regulated by EFSA. The European Food Safety Authority (EFSA) states that human intervention studies are ‘central’ to health claim substantiation and are also the ‘top of the hierarchy’ that informs decisions. Just how much data is necessary to deliver ...

Julien Tremblin, European GM of TerraCycle, an innovator in sustainability solutions, shares how companies large and small can drive change, in and out of the pharmaceutical industry and how retailers, brands and consumers are reacting, pushing and adopting as they transition from linear to circular soluti...

In today’s world, medical innovations and pharmaceutical technology are essential drivers of human health: they open up the possibility of new treatments and subsequently act as a gateway which allows people around the world to access new medicines, improving their quality of life.

In the produc...

Resyca, a joint venture between Recipharm and Medspray, is developing a novel type of soft mist inhaler devices, based on an existing primary packaging: glass pre filled syringes. This way we can utilise existing filling lines within Recipharm to do the aseptical filling. The lecture will describe the devi...

Antheia is a synthetic biology company developing rapid-response biomanufacturing processes for Active Pharmaceutical Ingredients and Key Starting Materials. In this session, Christina Smolke, PhD, CEO and co-founder of Antheia will dive into synthetic biology as a manufacturing technology and its potentia...

• A review of how big pharma has reacted to the trend: who is going virtual with their trials? • The usage data of virtual trial elements pre and post pandemic • Predictions for the future

Technological innovation in Pharma and Life Science is happening now!

Metaverse, Artificial Intelligence, Data Analytics, Machine Learning, Digitalization: these topics are ranking high on the agenda of the business leaders who understand the competitive advantages that can be seized by moving n...

According to the WHO, “Increasing the effectiveness of adherence interventions may have a far greater impact on the health of the population than any improvement in specific medical treatments.”

Unfortunately, many of the available interventions are cumbersome, inaccessible and or too expensive...

Have you wondered what value digital health brings to health systems?

This session will cover the ~25 main digital health value pools on health system level and show what value digital health solutions provide. In addition, digital health reimbursement is addressed, with a particular focus on t...

Advanced therapy clinical trials are growing, with a record number of therapies being approved in 2021. This increase in approvals has led many to predict that the commercialization of advanced therapies is not far away

It offers the potential for fantastic breakthroughs for patients. But it’s v...

The demand for localization of pharma products in the countries of the MEA region is booming ! Are the know how and the local infrastructures ready? Is there a clear understanding of the processes? What is the best business model and partnership when it comes to tech transfer? Case Study: Reshaping of KSA...

In the throes of the COVID-19 pandemic, global healthcare systems increased their focus on providing medicines outside of a hospital setting, whether that be in outpatient clinics, mobile clinics, pharmacies or at-home care. As a result, pharma companies have a unique opportunity to seize on this momentum ...

Polysorbates are intensively used in biologics formulation as stabilizer due to their propensity to inhibit aggregation at interfaces but possess low intrinsic stability. In this study, the chemical stability of KLEPTOSE® HPBCDs are compared with polysorbates under various stress conditions.

Wh...

This leadership-powered panel discussion will touch upon some of the actions, challenges and the way ahead for producers of fine chemicals to achieve manufacturing excellence through sustainable competitiveness, growth and the promotion of responsible global environmental performance.

Container closure integrity (CCI) testing is determined by evaluating whether a given container maintains its sterile barrier. It is a mandatory step in the design verification phase of a drug – device combination product development. Several methods exist with different advantages and limitations.
...

• Introduction-Pharmaceutical Industry Review Magazine- Svitlana Havrylenko, Editor in Chief, Pharmaceutical Industry Review Magazine • Ministry of Health - Oleksandr Komarida, First Deputy, Minister of Health of Ukraine • Ukrainian Pharma Market overview for the 1st half of Y2022. Market in war tur...

On Demand Pharmaceuticals is creating technology platforms that enable point-of-care medicine manufacturing whether on the battlefield or hospital. By building modular automated systems that can produce raw materials to finished drug product, we are strengthening medicine supply chain resiliency and transf...

The pipeline for advanced genetic therapies has grown exponentially since 2014, and now totals over 3,500 different developmental candidates. This session provides a comprehensive global snapshot of this R&D landscape, spanning gene, cell, and RNA-based drug modalities. This includes analysis of drug pipel...

This session will help you understand real-world life as a student entering the Pharma industry post-pandemic. We will learn more about the role a CDMO plays in the pharmaceutical industry and the importance of hiring university and school early careers from the lens of a business leader. Finally, we will ...

Novai is commercialising DARC, a combination biomarker consisting of Annexin A5 conjugated to a fluorophore (Dy776). ANX776 binds to stressed/apoptotic retinal cells which are visualisable as white spots using equipment routinely used by opticians, optometrists, and ophthalmologists. The images are then an...

Cell and gene therapies are at the forefront of personalised and precision medicines. By better understanding and harnessing the human body’s own biological/immunological processes to fight or even cure disease, these “living drugs” hold tremendous promise for millions of patients with high unmet medical n...

mRNA has been called the software of life. It can help treat everything from cancer to cardiovascular diseases and can be used on high-scale as well as for niche indications. Covid-19 has put mRNA technology in the spotlights. The technology is therefore appealing to investors. However, how are these medic...

In this session you hear from Johannes Galatsanos, Head of Data - Lean Digital Core ERP Transformation from Novartis.

Understanding and channeling ourselves to think about the intersection of sustainability, quality, and supply chain integrity within pharmaceuticals. This relationship has become significant as we enter the post pandemic era in which the pharmaceutical industry strives to not only secure its supply chain a...

In recent years, the standardization of biologics manufacturing processes has given product developers multiple viable options for producing biologics. These options include building an in-house production system or partnering with a contract biologics manufacturer. Although building in-house does offer th...